The vision of the SINPAIN is to improve the quality of life for those affected by OA and reduce the substantial costs linked with the disease by developing a new generation of OA therapeutics.

Osteoarthritis (OA) is one major course of years lived with disability in the elderly and considered a high burden disease. There is no cure for OA and available treatments needs to be reconsidered. Current pharmacological interventions consist mainly of analgesic and anti-inflammatory drugs with the addition of intraarticular steroids and hyaluronic acid (IA- HA) injections.

Nevertheless, all with moderate efficacy and associated long-term side effects. Taking advantage of the explosion of RNA technologies in the last years, SINPAIN aims to develop a pipeline of siRNA-based therapy built on the combination of current technologies (dynamic IA-HA and nanocarriers) that will be designed step- by-step in order to reach a successful management of inflammation and innervation therapy for the treatment of early (grade 0-1) and later stages (grade 3-4) of knee OA. Exploiting the data obtained during the project, a decision-making tool based on machine learning will be validated to offer patients a personalized therapy. 

In the EU research project UPO is leading imaging mass cytometry and single cell transcriptomic/proteomic research on the biopsies of the OA affected individuals. UPO is custom-designing and validating imaging mass cytometry panels in order to precisely identify blood vessels, synovial cells, cartilage, nerve fibbers, pericytes, T and B-cell, and macrophages. 

UPO is also participating in the assessing of efficacy of the clinically relevant in vivo OA model and in demonstrating in vivo biocompatibility of the advanced nanotherapeutic cell. 

The vision of the SINPAIN is to improve the quality of life for those affected by OA and reduce the substantial costs linked with the disease by developing a new generation of OA therapeutics.

Osteoarthritis (OA) is one major course of years lived with disability in the elderly and considered a high burden disease. There is no cure for OA and available treatments needs to be reconsidered. Current pharmacological interventions consist mainly of analgesic and anti-inflammatory drugs with the addition of intraarticular steroids and hyaluronic acid (IA- HA) injections.

Nevertheless, all with moderate efficacy and associated long-term side effects. Taking advantage of the explosion of RNA technologies in the last years, SINPAIN aims to develop a pipeline of siRNA-based therapy built on the combination of current technologies (dynamic IA-HA and nanocarriers) that will be designed step- by-step in order to reach a successful management of inflammation and innervation therapy for the treatment of early (grade 0-1) and later stages (grade 3-4) of knee OA. Exploiting the data obtained during the project, a decision-making tool based on machine learning will be validated to offer patients a personalized therapy. 

In the EU research project UPO is leading imaging mass cytometry and single cell transcriptomic/proteomic research on the biopsies of the OA affected individuals. UPO is custom-designing and validating imaging mass cytometry panels in order to precisely identify blood vessels, synovial cells, cartilage, nerve fibbers, pericytes, T and B-cell, and macrophages. 

UPO is also participating in the assessing of efficacy of the clinically relevant in vivo OA model and in demonstrating in vivo biocompatibility of the advanced nanotherapeutic cell.